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Background
The indications for gastrectomy in T4 gastric carcinoma
(GC) remain controversial. Our aim was to develop a
method for the selection of patients with T4 GC with the
best chances to receive a benefit from multiorgan resec-
tion.
Materials and methods
We study a cohort of patients with T4 GC treated from Jan-
uary 1987 to December 2005. Relevant clinical, patholog-
ical and therapeutic variables were recorded. Prognostic
factors associated with survival were defined by Kaplan-
Meier and Cox's methods. Factors associated to surgical
morbidity were selected by Logistic Regression analysis.
Results
718 patients were included (gastrectomy performed in
169). The clinical and pathological characteristics of the
cohort depending on the residual status after the surgery
was recorded. Presence of metastasis (Hazard ratio = 1.68
[HR], 95% confidence interval [CI] 1.19–2.36), albumin
<3 g/dL plus lymphocytes <1000 cells/mm3 (HR = 2.9,
95% CI 1.8–4.6), presence of ascites (HR = 2.1, 95% CI
1.06–4.2), 50 years old or more (HR = 1.37, 95% CI 1.02–
1.8) and absence of surgical resection (HR = 2.6, 95% CI
1.7–4.1) define patients with the worst prognosis (model
p = 0.00001). Including only patients underwent surgical
resection, presence of metastases, extent of gastrectomy,
serum albumin level and R1–R2 residual were determi-
nants of poor survival (model p = 0.00001). Surgical mor-
bidity and mortality were 39% and 10.7%, respectively.
The significant determinants of surgical morbidity were
extent of gastrectomy, age, serum albumin and lym-
phocyte count (model p = 0.0001).
Conclusion
The decision to perform a curative gastrectomy in patients
with T4 GC must be balanced between the chances of
long-term survival and the chances of surviving a poten-
tially fatal operation. We propose a simple method to
select those patients with high probability of benefiting
from the procedure.
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